In recent years, institutions across the globe have begun researching how virtual reality could be utilized in mental health ...
Vitamin D supplementation may help manage hypertension, particularly in older adults with overweight or obesity, a new study ...
Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good morning, and welcome to the Axsome Therapeutics Third ...
The agency has placed a partial hold on the phase 2a PORTOLA trial evaluating the selective immunoproteasome inhibitor ...
The MANEUVER study met the primary endpoint with an objective response rate (ORR) at week 25 of 54.0% compared with 3.2% for placebo (p- Statistically significant ...
The primary objective of this Phase 1 randomized, double-blind, placebo-controlled, multi-part single and multiple ascending dose clinical study is to evaluate the safety, tolerability and ...
The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.
Monthly 140 mg erenumab injections are a safe and effective treatment for patients with nonopioid chronic migraine and medication overuse headaches.
Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...
The Study 304 (NCT04959032) trial met its primary endpoint of time to relapse during the 26-week double-blind treatment phase, with Caplyta treatment associated with a 63% reduction in the risk of ...
Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback